SCHEMBL2666595

SCHEMBL2666595

CN/N=C\S

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL684683 0.64
SCHEMBL4400439 0.64
SCHEMBL2295450 0.64
SCHEMBL15832920 0.61
SCHEMBL2666520 0.61
SCHEMBL15833687 0.61
SCHEMBL13780560 0.61
SCHEMBL6262421 0.59
SCHEMBL6839430 0.59
SCHEMBL15159645 0.57

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015117912-A1 PESTICIDALLY ACTIVE AMIDE DERIVATIVES WITH SULPHUR CONTAINING SUBSTITUENTS SYNGENTA PARTICIPATIONS AG (CH) 2015-08-13 WO disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-20130072492-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS MERCK SHARP & DOHME LLC 2013-03-21 US disclosed
EP-2554540-A2 3-Cyclyl-2-(4-sulfamoyl-phenyl)-n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes Novartis AG (CH) 2013-02-06 EP disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
US-8252931-B2 Thiazolo[5,4-B]pyridine glucokinase activators NOVARTIS AG (CH) 2012-08-28 US disclosed
EP-1930172-B1 OPTICAL RECORDING MEDIUM, AZO-TYPE IRON CHELATE COLORING MATTER, AND AZO-TYPE METAL CHELATE COLORING MATTER ADDITIVE MITSUBISHI KAGAKU MEDIA CO LTD (JP) 2012-07-04 EP disclosed
US-20120108614-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES HYDRA BIOSCIENCES, INC. 2012-05-03 US disclosed
WO-2012020357-A1 ACETAMIDE COMPOUNDS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION ADVINUS THERAPEUTICS LTD. (IN) 2012-02-16 WO disclosed
EP-2298779-A1 Sulfonamide derivatives as glycokinase activators useful in the treatment of type 2 diabetes Novartis AG (CH) 2011-03-23 EP disclosed
US-20100324021-A1 (DIHYDRO)IMIDAZOISO[5,1-A]QUINOLINES N.V. ORGANON (NL) 2010-12-23 US disclosed
US-7605174-B2 Indane derivatives as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-10-20 US disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
US-20080312256-A1 Organic Compounds NOVARTIS AG (CH) 2008-12-18 US disclosed
WO-2007041365-B1 3-CYCLYL-2- (4-SULFAMO YL-PHENYL) -N-CYCLYL-PROPIONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF IMPAIRED GLUCOSE TOLERANCE AND DIABETES NOVARTIS AG (CH) 2007-08-16 WO disclosed
US-20070117801-A1 Indane derivatives as modulator of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-05-24 US disclosed
WO-2007041365-A2 3-CYCLYL-2- (4-SULFAMO YL-PHENYL) -N-CYCLYL-PROPIONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF IMPAIRED GLUCOSE TOLERANCE AND DIABETES NOVARTIS AG (CH) 2007-04-12 WO disclosed
WO-2007041366-A1 SULFONAMIDE DERIVATIVES AS GLYCOKINASE ACTIVATORS USEFUL IN THE TREATMENT OF TYPE 2 DIABETES NOVARTIS AG (CH) 2007-04-12 WO disclosed